Health knowledge made personal
Join this community!
› Share page:
Search posts:

Vaccine to Prevent BK Polyomavirus-associated Kidney and Bladder Infections in Organ Transplant Recipients

Posted Aug 29 2011 8:00pm

Description of Invention:
Nearly all adults have chronic urinary tract infections with one or more strains of BK polyomavirus (BKV). In healthy persons, the infection is controlled by the immune system and no symptoms are apparent. However, immunosuppressed persons, such as organ transplant recipients, can suffer from bladder disease or kidney disease caused by uncontrolled BKV growth. BKV causes cancer in animals; it is unknown if the same is true in humans. A significant need remains for a means of preventing BKV infection and associated pathologies.

Researchers at the National Cancer Institute, NIH, have developed compositions and therapeutic methods for pre-vaccination of organ transplant recipients against BKV and prognostic methods to identify patients that may benefit from the vaccination. Methods for producing a BKV vaccine against all four known BKV serotypes are in development.

  • An effective multivalent BKV vaccine to prevent BKV-associated pathologies of the urinary tract and bladder.
  • A prognostic kit to determine clinical benefit.
  • Tests for identifying renal transplant donors and recipients.

  • A successful proof-of-principle study in mice has been conducted.
  • The inventors have identified the major virulent BKV serotype.
  • No vaccine for BKV infection currently exists.
  • If BKV is linked to cancer, the technology might be relevant to vaccines applicable to the general public.

Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)

Christopher B Buck (NCI)
Diana V Pastrana (NCI)

Patent Status:
HHS, Reference No. E-168-2011/0
US, Application No. 61/508,897 filed 18 Jul 2011

Relevant Publication:
  1. In preparation

Collaborative Research Opportunity:
The NCI Center for Cancer Research, Laboratory of Cellular Oncology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact John Hewes, Ph.D. at .

For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-496-7057
Fax: 301-402-0220

Ref No: 2311

Updated: 08/2011

Post a comment
Write a comment:

Related Searches